| nintedanib / Generic mfg. |
2015-004919-20: A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) Studio pilota sul Nintedanib nella Linfangioleiomiomatosi ( LAM ) |
|
|
| Ongoing | 3 | 30 | Europe | Capsule, soft, Ofev | MULTIMEDICA S.P.A., B.4.1 Azienda Farmaceutica: Boehringer Ingelheim Pharma GmbH &Co. KG | Female subjects affected by Llymphangioleiomyomatosis (LAM) La linfangioleiomiomatosi(LAM)è una malattia multisistemica che colpisce prevalentemente le donne in età fertile.E’ caratterizzata da proliferazione di cellule muscolari lisce anomale(cellule LAM)che causano la formazione di cisti aeree all’interno del polmone,alterazioni cistiche lungo il decorso dei vasi linfatici(linfangioleiomiomi)e angiomiolipomi, tumori benigni generalmente riscontrati nel rene.Può essere sporadica o interessare fino al 80% delle donne affette da Sclerosi Tuberosa (TSC)., ymphangioleiomyomatosis (LAM) is a rare, progressive, systemic disease that typically results in cystic lung destruction and predominantly affects women, especially during child bearing years Malattia del polmone caratterizzata da sostituzione della normale architettura del polmone con cisti aeree., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2018-001747-31: A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2 Essai multicentrique, randomisé double aveugle contre placebo, évaluant l'efficacité du Nintedanib dans le traitement du Syndrome de Bronchiolite Oblitérante de grade 1-2 chez les patients transplantés pulmonaires. |
|
|
| Not yet recruiting | 3 | 80 | Europe | Capsule, OFEV | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation. Syndrome de Bronchiolite Oblitérante (SBO) de grade 1 ou 2 chez des patients patients greffés pulmonaires ., bronchiolitis obliterans syndrome Syndrome de Bronchiolite Oblitérante de grade 1-2, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2019-004326-19: Management of Progressive Disease in Idiopathic Pulmonary Fibrosis Prise en charge pragmatique de la fibrose pulmonaire idiopathique en progression |
|
|
| Not yet recruiting | 3 | 378 | Europe | Capsule, Capsule, soft, pirfenidone, nintedanib | Hospices Civils de Lyon, Ministry of Health | Idiopathic pulmonary fibrosis fibrose pulmonaire idiopathique, Idiopathic pulmonary fibrosis Fibrose pulmonaire idiopathique, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2020-002114-40: Nintedanib for the treatment of pulmonary fibrosis induced by Covid-19 |
|
|
| Not yet recruiting | 3 | 250 | Europe | Capsule, soft, OFEV 150 mg, OFEV 100 mg | Assistance Publique - Hôpitaux de Paris, Ministery of Health | Patients 2 to 6 months after Covid-19 acute pneumonia, patients 2 to 3 months after acute pneumonitis induced Covid-19 infection, Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | | | | |
| Recruiting | 3 | 250 | Europe | Nintedanib 150 MG [Ofev], Placebo, NaCl | Assistance Publique - Hôpitaux de Paris, Boehringer Ingelheim | SARS-Cov-2 Induced Pulmonary Fibrosis | 10/23 | 07/24 | | |
| Recruiting | 3 | 80 | Europe | Nintedanib, Placebo | Assistance Publique - Hôpitaux de Paris | Lung-transplant Recipients | 01/25 | 05/25 | | |
NINTOC-TU, NCT06297096: Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease |
|
|
| Not yet recruiting | 3 | 86 | Europe | Tocilizumab, Nintedanib, Standard therapy, mycophenolate mofetil, methotrexate | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland, Medical Research Agency, Poland | Systemic Sclerosis, Interstitial Lung Disease | 12/27 | 03/28 | | |
NCT05065190: A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis |
|
|
| Completed | 3 | 81 | RoW | nintedanib, Placebo | Boehringer Ingelheim | Lung Diseases, Interstitial | 04/24 | 05/24 | | |
NCT05067517: Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease |
|
|
| Not yet recruiting | 3 | 160 | US | Nintedanib, OFEV, Placebo | West Virginia University | Progressive Fibrosing Interstitial Lung Disease | 07/24 | 07/24 | | |
NCT05285982 / 2020-005554-23: A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON) |
|
|
| Active, not recruiting | 3 | 54 | Europe, Canada, US, RoW | Nintedanib (Ofev®) | Boehringer Ingelheim | Lung Diseases, Interstitial | 07/25 | 08/25 | | |
ChiCTR2300070492: Nintedanib in Prevention of Pulmonary Fibrosis in Malignant Ovarian Germ Cell Tumor Patients Receiving Bleomycin: A randomized, double-blind, controlled trial |
|
|
| Not yet recruiting | 3 | 116 | | standard BEP regimen chemotherapy with nintedanib 150mg bid po till the end of treatment ;standard BEP regimen chemotherapy with plabeco 150mg bid po till the end of treatment | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Malignant Ovarian Germ Cell Tumor | | | | |
NCT05635071: Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions |
|
|
| Not yet recruiting | 2/3 | 90 | NA | Nintedanib 100 MG [Ofev], Nintedanib 100 MG Oral Capsule, Nintedanib 150 MG [Ofev], Nintedanib 150 MG Oral Capsule | Sixth Affiliated Hospital, Sun Yat-sen University | Uterine Adhesions | 07/24 | 12/24 | | |
